459 related articles for article (PubMed ID: 25136066)
21. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
22. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
23. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
24. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
25. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
26. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
27. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
[TBL] [Abstract][Full Text] [Related]
29. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Ogawa T; Liggett TE; Melnikov AA; Monitto CL; Kusuke D; Shiga K; Kobayashi T; Horii A; Chatterjee A; Levenson VV; Koch WM; Sidransky D; Chang X
Cell Cycle; 2012 Apr; 11(8):1656-63. PubMed ID: 22487682
[TBL] [Abstract][Full Text] [Related]
30. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
32. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
33. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
34. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
[TBL] [Abstract][Full Text] [Related]
35. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
36. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
37. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.
Boeckx C; Op de Beeck K; Wouters A; Deschoolmeester V; Limame R; Zwaenepoel K; Specenier P; Pauwels P; Vermorken JB; Peeters M; Van Camp G; Baay M; Lardon F
Cancer Lett; 2014 Nov; 354(2):365-77. PubMed ID: 25192874
[TBL] [Abstract][Full Text] [Related]
38. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
[TBL] [Abstract][Full Text] [Related]
39. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
40. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
